Alzheimer's disease (AD)-linked mutations in Presenilins (PSEN) and the amyloid precursor protein (APP) lead to production of longer amyloidogenic Ab peptides. The shift in Ab length is fundamental to the disease; however, the underlying mechanism remains elusive. Here, we show that substrate shortening progressively destabilizes the consecutive enzyme-substrate (E-S) complexes that characterize the sequential g-secretase processing of APP. Remarkably, pathogenic PSEN or APP mutations further destabilize labile E-S complexes and thereby promote generation of longer Ab peptides. Similarly, destabilization of wild-type E-S complexes by temperature, compounds, or detergent promotes release of amyloidogenic Ab. In contrast, E-Ab n stabilizers increase g-secretase processivity. Our work presents a unifying model for how PSEN or APP mutations enhance amyloidogenic Ab production, suggests that environmental factors may increase AD risk, and provides the theoretical basis for the development of g-secretase/substrate stabilizing compounds for the prevention of AD.
In Brief
Sequential g-secretase cuts on amyloid precursor protein (APP) generates progressively less stable enzymesubstrate (E-S) complexes. Alzheimer's disease-causing mutations destabilize E-S complexes and thereby enhance amyloidogenic Ab production.
INTRODUCTION
Finding a therapy for Alzheimer's disease (AD) is one of the biggest challenges of current medicine. Genetics has shown that single mutations in functionally related genes cause early onset familial AD (FAD) in an autosomal dominant manner, providing a unique model to investigate AD pathogenic mechanisms. More than 200 mutations in Presenilin 1 or 2 (PSEN1/2) (Enzyme) (Sherrington et al., 1995) and about 20 in the amyloid precursor protein (APP) (Substrate) (Goate et al., 1991) strongly support the relevance of Ab (Products) in AD pathogenesis. PSEN1/2 are the catalytic subunits of distinct g-secretase intramembrane protease complexes (De Strooper et al., 1998; Wolfe et al., 1999) , which additionally contain Nicastrin (NCT), Presenilin-enhancer 2 (PEN2), and the anterior pharynx defective 1 (APH1) as essential components .
Several studies point to long Ab peptides (RAb 42 ) as key players in the initiation of aggregation of toxic APP-derived Ab species, which ultimately lead to neurodegeneration in AD Haass and Selkoe, 2007) . Thus, understanding the mechanisms that define the Ab product length is highly relevant for the development of efficient strategies that target toxic Ab production as part of AD disease-modifying therapy.
g-Secretases generate Ab peptides of different lengths from APP, and AD causative PSEN mutations consistently decrease g-secretase processivity (number of cuts per substrate molecule), thereby shifting Ab profiles toward longer and more amyloidogenic peptides (Chá vez-Gutié rrez et al., 2012; Fernandez et al., 2014) . Although highly relevant, mechanistic understanding of g-secretase function is very limited. For instance, we do not know how g-secretase recognizes substrates, what drives the sequential cleavage of APP, or how clinical mutations in PSEN lead to the release of longer Ab peptides. Such lack of fundamental insights has allowed controversies about the pathogenic role of PSEN to grow (Veugelen et al., 2016) .
Recent structural studies on g-secretase (Bai et al., 2015a (Bai et al., , 2015b (Figure S1A ) revealed that PSEN adopts a loosely organized, likely metastable, fold that co-exists in several conformations. These findings are in line with previous low-resolution structural analyses (Elad et al., 2015; Li et al., 2014) and with FRET-based studies presenting the PSEN/ g-secretase complex as a very dynamic entity (Lleó et al., 2004; Uemura et al., 2009 Uemura et al., , 2010 Wahlster et al., 2013) .
Interestingly, elegant studies also depict the rhomboid intramembrane proteases as intrinsically metastable proteolytic systems (Baker and Urban, 2012) . Given that protein stability results from a cooperative network of weak interactions, scattered distributed mutations throughout a structure can destabilize the entire native fold (Freire, 1999) . If PSEN structure, as rhomboids, relied on a network of weak interactions throughout the molecule, one could hypothesize that scattered FAD-linked PSEN mutations might further ''destabilize'' its metastable fold and could impact protease function.
g-Secretase displays a complex proteolytic activity (Takami et al., 2009 ). An initial ε-endopeptidase cleavage releases the soluble intracellular domain (AICD) and generates a long Ab fragment (either Ab 49 or Ab 48 ) that is successively cut by carboxypeptidase-like g-cleavages, generating shorter Ab n peptides ( Figure 1A ) until Ab release stops the process. Accordingly, the sequential processing of APP by g-secretase involves the formation of distinct enzyme-substrate (E-S) complexes, with each of them containing shortened de novo Ab n substrates.
We hypothesized that the stability of each E-S complex determines the probability of its dissociation and thereby the length of Ab peptides released (Ab profiles). To investigate this possibility, we performed thermoactivity assays to quantitatively evaluate the stability of E-S complexes. We demonstrate that E-S complexes formed between wild-type g-secretase and APP/Ab n become progressively less stable with shortening of the substrates. Furthermore, pathogenic PSEN mutations consistently destabilize the E-S interaction with APP-and Abn-substrates, leading to enhanced dissociation/release of aggregation-prone, longer Ab peptides. Significantly, several FAD-causing APP mutations destabilize the E-S complex and prime ''de novo long Abs'' for dissociation. These studies provide a unifying and coherent rationale for how FAD causative mutations affect g-secretase processivity. Of importance for sporadic AD, fever-range-temperature-or exogenous-compound-induced destabilization of wild-type E-S complexes in vitro and in vivo is sufficient to produce amyloidogenic Ab peptides. Our work opens new avenues for the discovery of g-secretase-Abn stabilizing compounds (GSSC) as potential therapeutics for AD.
RESULTS
Progressive Destabilization of Wild-Type g-Secretase-APP Interactions Leads to FAD-like Ab Profiles g-Secretase sequentially cuts APP to generate Ab peptides of different length (Ab n ) (Takami et al., 2009 ) in a process that involves the formation of distinct E-S complexes ( Figure 1A ). To investigate the relative stabilities of the consecutive E-S complexes, we performed in vitro g-secretase activity assays across a temperature gradient (from 37 C to 65 C), using purified PSEN1/Aph1A g-secretase and the APP C99 -3XFLAG substrate. Increments in temperature from 37 to 55 C had a modest effect on the initial endopeptidase ε-cleavage (100 ± 15%) ( Figure 1B ) but progressively decreased enzyme processivity, as indicated by the increase in production of long Ab peptides ( Figure 1C ).
Specifically, quantitative analyses of substrates (Ab 42 and Ab 43 ) and products (Ab 38 and Ab 40 ) of the fourth g-secretase catalytic cycle demonstrates the progressive drop in enzyme processivity ( Figure 1D ). This provides an estimate of their ''optimum temperature'' of production as well as the temperature at which production drops to 50% of the initial levels at 37 C (Tm) ( Figure 1E , dotted line). The optimum temperatures for Ab 38 (95% CI [confidence interval] = 31.9 C-36.9 C), Ab 40 (95% CI = 38.3 C -40.7 C), Ab 42 (95% CI = 43.9 C-46.4 C), and Ab 43 (95% CI = 47.8 C-49.6 C) directly correlate with the length/hydrophobicity of the corresponding peptide, and the same conclusion can be derived from the Tm values (Table S1 for Tm ± 95% CI). Our data reveal that the E-S complex stability correlates with the substrate length, implying that sequential g-secretase cleavages on APP progressively decrease E-S stabilities and thus increase the probability of E-S dissociation and Ab release.
Next, we evaluated the temperature dependencies of the g-secretase ε-cleavage of Notch ( Figure 1F ) (De Strooper et al., 1999) . The results (Figures 1G versus 1B; Tm 95% CI: 57.4 C-59.2 C versus 60.0 C-62.4 C, Notch and APP respectively) indicate that, although distinct, the stabilities of both APP and Notch (ε-) E-S complexes are higher than any of the (g-) E-Ab n complexes (Table S1B) . Thus, despite strong differences in primary sequence, longer (ε)-substrates display higher stability of E-S interactions than seen with shorter (g) substrates.
The relative higher stability of the endoproteolytic cleavage (versus the g-cleavages) implies that the associated physiologically relevant signaling cascades mediated by ε-cleaved intracellular protein domains are relatively more resistant to destabilizing perturbations.
Membrane Components Stabilize g-Secretase-

Substrate Interactions
The evaluation of g-secretase kinetics in CHAPSO-solubilized conditions is a common practice in the field. However, compared to cell-based assays (Sato et al., 2003) , these conditions promote the generation of long Ab R42 peptides. Based on the experimental evidence above, we hypothesized that detergent extraction, similar to increasing temperature, might destabilize g-secretase and therefore impair processivity. Hence, we assessed g-secretase function in CHAPSO-resistant membranes (DRMs), an alternative and well-validated cell-free system for the study of g-secretase activity (Kakuda et al., 2012; Matsumura et al., 2014; Szaruga et al., 2015; Wahrle et al., 2002) that yields similar Ab ratios as cell-based assays (Figures S1B and S1C). We prepared DRMs from five post-mortem human brain samples of control subjects. Thermal analysis of ε-endopeptidase activity evaluated by de novo AICD generation revealed no detrimental changes over the 37 C-65 C temperature interval ( Figure 1H ), demonstrating the stabilizing effect of DRMs on ε-activity ( Figures 1H versus 1B) . In contrast, a mild increment in temperature significantly affected g-secretase processivity (73.2% ± 10.0 at 40 C; mean of means ± SD) ( Figure 1I ), and remarkably, further temperature increments reduced processivity to the levels seen in FAD patient brain samples (59.4% ± 2.3 at 45 C and 20.3% ± 5 at 55 C; mean of means ± SD of control brain DRMs versus 44.4% ± 13.6 at 37 C mean of means ± SD of 22 FAD brain DRMs; data for FAD taken from Figure 2 in [Szaruga et al., 2015] ). These studies demonstrate that the membrane environment shapes Ab profiles by stabilizing the most labile g-secretase-Ab n complexes and that thermal destabilization of wild-type g-secretase leads to Ab profiles similar to those seen in FAD.
Ab n Substrate Length Is a Determinant for E-S Complex Stability
Given that E-S complexes containing relatively long Ab n peptides (n = 45, 43, and 42) are the most labile and therefore susceptible to dysregulation, we investigated the processing of (B-E) In vitro activity assays with purified wild-type human g-secretase (PSEN1/APH1a) and APP C99 -3xFLAG over a temperature gradient. (B) Total AICD-3xFLAG product levels analyzed by quantitative western immunoblot (top) reveal similar AICD product levels (100 ± 15%) in temperatures ranging from 37 C to 55.1 C (white background, bottom). Gaussian fitting indicates an optimal AICD production temperature of 44.8 C ± 0.6 C for AICD, (mean ± SE, n > 5 products reveal a correlation between the optimal temperature of production (interpolated, vertical lines) and peptide length (maximal interpolated Ab levels adjusted to 100%; mean ± SEM, n = 4). (F) Endopeptidase (ε) and carboxypeptidase-like (g) cleavage sites on transmembrane domains of APP (Takami et al., 2009) or Notch1 substrates (Okochi et al., 2006 ) (black and gray arrows describe the two APP production pathways; [A]). (G) Thermoactivity assays with purified wildtype g-secretase show significant differences in thermal susceptibilities of the ε-cleavages of Notch-3xFLAG (data in red) (mean ± SD, n = 3) versus APP C99 -3xFLAG (data in gray, [B] , P value < 0.01). Dotted lines through the manuscript indicate the temperatures at which production reaches 50% of their initial levels at 37 C (Tm).
(H and I) In vitro activity assays using DRMs prepared from postmortem human brain samples and APP C99 -3xFLAG as substrate were incubated over a temperature gradient. (H) De novo AICD levels determined by quantitative western blot (top) show no significant changes over the 37 C-55 C temperature interval (mean of means ± SD, five patient samples, n R 2). (I) ELISA-quantified Ab 38 and Ab 42 products demonstrate that increments in temperature lead to progressive impairment in g-processivity, specifically at the 4 th catalytic turnover; (mean of means ± SD, four patient samples, n = 2, One-way ANOVA and Dunnett's post-test p < 0.0001). Previously published Ab 38/42 ratios (Szaruga et al., 2015) were determined at 37 C for DRMs prepared from postmortem brain samples of 22 FAD patients carrying nine different PSEN mutations (gray area, mean of means ± SD). Table S2 ). The importance of substrate length for E-S stability is further illustrated by the observation that generation of Ab 43 from Ab 46 occurs with similar efficiencies at 37 C and 51 C ( Figure 2B ; Table S2 ), while its further conversion (in the same reaction mix) to Ab 40 drastically decreases ($82%) at 51 C ( Figure 2C ). Similarly, the Ab 40 /Ab 43 and Ab 38 /Ab 42 ratios ( Figure 2G ), which provide estimates for the efficiencies of the corresponding cleavages, indicate that (B, C, E-G) Thermoactivity assays using purified g-secretase and synthetic Ab 46 (C) and (F) (mean ± SEM, t test, P value < 0.0001).
(H) Sequential g-secretase cuts on APP progressively decrease E-S complex stability and increase the probability of dissociation.
g-secretase cuts Ab 43 more efficiently than Ab 42 already at 37 C. In addition, we investigated the processing of the synthetic Ab 43 by wild-type g-secretase. This peptide was cut in a ''oneturnover'' process, as no Ab 37 was generated in the assay, and its conversion to Ab 40 occurred very inefficiently already at 37 C ( Figure S2 ) ($0.2% of the efficiency of Ab 45 to Ab 42 at 37 C). Remarkably, the efficiency of the Ab 43 to Ab 40 cleavage is higher when a ''de novo Ab 43 '' (generated from Ab 46 ) is processed than when Ab 43 is given as initial substrate (Figures 2G versus S2) . This suggests that pre-established interactions between enzyme and Ab precursor contribute to the stability of the newly generated E-Ab n complex.
The decreasing stabilities of E-S complexes with peptides <Ab 46 strongly point to a critical Ab substrate length for efficient g-cleavage processing. Remarkably, the effect of temperature on the catalytic efficiencies is explained by decreased proteolytic rates (Vmax) ( Table S2 ) rather than by changes in affinity (Km) as will be discussed below. Finally, determination of the apparent substrate equilibrium dissociation constant (Kd) revealed a substantial difference between the relative affinities for APP C99 versus Ab 43 , Ab 40 , and Ab 38 peptides ( Figure S3A ; Table  S4 ). Thus, providing direct experimental evidence that substrate length affects the strength of E-S interactions ( Figure 2H ).
AD-Linked PSEN Mutations Destabilize g-SecretaseSubstrate Complexes
We next investigated the effect(s) of AD-linked PSEN mutations on the stability of the g-secretase cleavages. We selected eight pathogenic PSEN1 mutations (P88L, Y115H, M139V, L166P, R278I, E280A, G384A, and L435F) that impair the ε-endo and g-carboxypeptidase-like activities to different extents and that differ in age of onset and location throughout PSEN1 (Figures 3A and 3B; Table S3 ). The R278I and L435F mutations additionally affect activation of the g-secretase pro-enzyme (PSEN auto-proteolysis) and drastically reduce levels of the active g-secretase in cells (Saito et al., 2011; Veugelen et al., 2016) . Thermoactivity assays using purified wild-type or mutant g-secretase complexes and the APP C99 -3XFLAG substrate reveal that PSEN mutations consistently shift Tm values for AICD-3XFLAG ( Figure 3C ), Ab 38 , Ab 40 , and Ab 42 production ( Figure 3D , upper, middle, and lower panels, respectively). Thus, clinical mutations consistently destabilize, to different extents, the productive interaction with APP C99 and de novo Ab n substrates, relative to the wild-type enzyme (Table S1 ).
To investigate the underlying cause of the observed destabilization of E-S complexes by PSEN mutations, we evaluated directly their effects on the intrinsic stabilities of the protease. We subjected purified wild-type and mutant enzymes to increasing temperatures for 15 min and subsequently pelleted the thermally induced aggregates by ultracentrifugation. The remaining soluble PSEN NTF and CTF fractions were quantified by immunoblot. All tested FAD mutations increase aggregation propensities and thus impair the intrinsic g-secretase thermostability ( Figures S4A and S4B) . Furthermore, we show that conformation-sensitive nanobodies (Nb4-and Nb28) against g-secretase display less thermostable interactions with mutant g-secretases (PSEN1-L166P, E280A, or G384A) than with the wild-type complex ( Figure S4C , dotted line) ( Figure S4C , dotted line).
The P88L, R278I, and L435F g-secretase complexes drastically reduce the endopeptidase activity and produce mostly Ab 43 and longer peptides at 37 C (Ohki et al., 2014; Saito et al., 2011; Veugelen et al., 2016) . The activities of these mutants rapidly decay with increasing temperature (Figures 3C and S5) , indicating severe destabilization of the intermediary and initial E-S complexes. This likely explains their inefficient endo-and carboxypeptidase activities at normal body temperature. The other PSEN mutations display significant but relatively mild destabilizing effects on Ab 38 production ( Figure 3D , upper panel; see also the corresponding Tm values in Table  S1 ). Given that Ab 42 is the main precursor of Ab 38 , the relatively fast decay in Ab 38 production reflects the high probability of Ab 42 release. The destabilizing effects induced by pathogenic mutations become more clear when analyzing Ab 40 and Ab 42 generation, which reflects the processing of Ab 43 and Ab 45 substrates, respectively ( Figure 3D , middle and low panels). The Tm values (Table S1 ) determined for pathogenic PSEN variants are consistently lower than the corresponding wild-type values. These findings indicate that the destabilizing effects induced by PSEN mutations result in increased E-Ab n complex dissociation rates and hence enhance release of longer Ab peptides. We note that increased dissociation does not necessarily imply a lower affinity of the E-S interaction (Kd) as will be demonstrated below. The clinical relevance of the AD-mutant-induced destabilization of E-S complexes is supported by the remarkable correlation between the age of onset for five out of eight PSEN mutations and their destabilizing effects (Tm) for ε-endopeptidase ( Figure 3E ) or g-carboxypeptidase activity ( Figure 3F ). Intriguingly, patients carrying the P88L, R278I, and L435F mutations, which are the most impactful on g-secretase, have a ''delayed'' age of onset despite their drastic effect on g-processivity (generation of Ab R43 ). We propose that the extremely low global activity of the mutated allele counteracts the deleterious effects that may be associated with the enhanced production of long Ab peptides, therefore lowering the overall pathogenic effect and resulting in a later age at onset than would otherwise be seen.
AD-Linked APP Mutations Prime ''g-Secretase-Ab
Complexes'' for Dissociation Our studies place the E-S complex stabilities central to FAD pathogenesis; thus, we investigated whether pathogenic substitutions in APP affect these key assemblies. The T43I-, I45F-, V46F-, and V46I-APP mutations (Table S3) were chosen for thermoactivity analysis with wild-type g-secretase. At the endopeptidase level, three mutations exerted mild destabilizing effects, while T43I did not differentiate from the wild-type (Figure 4A ; Table S1 ). We then evaluated whether the destabilizing effects of clinical mutations in PSEN and APP were additive. For that, we selected the mild E280A-PSEN mutation ( Figure 3C ). Endoproteolytic processing of the V46F and I45F-APP substrates by the mutant E280A-PSEN1/g-secretase over a temperature gradient demonstrated additive destabilizing effects ( Figure 4B ; Table S1 ), indicating converging detrimental effects of APP and PSEN mutations. (B) 3D location of the selected PSEN1 mutations (red), except for the R278, which is not resolved in the 3D structure. Catalytic Asp residues shown in yellow.
(1) Lateral and (2) bottom views of PSEN1 structure (brown) with a co-purifying peptide (gray) (PDB: 5FN2). (C and D) Thermoactivity assays using purified wild-type or mutant g-secretase complexes and APP C99 -3xFLAG substrate incubated for 20 min at the indicated temperatures, except for the severe P88L mutant, which activity was measured after 1 hr and its concentration was 103 higher. (C) Representative immunoblots showing AICD-3XFLAG levels generated by the different protease complexes (top). Bottom: Gaussian fittings on AICD-3XFLAG product levels; (mean ± SEM, n = 4) (see Table S1A for Tm ± 95% CI). Null hypothesis (one curve for all datasets) rejected; different curves for each dataset with p < 0.0001. ( 
-E-S Complexes
(A and B) AICD product levels generated in thermoactivity assays from the indicated mutant APP C99 -3XFLAG substrates and purified (A) wild-type or (B) E280A-PSEN1 mutant g-secretase complexes. Gaussian fittings on de novo AICD-3XFLAG levels (mean ± SEM, n R 3). Different curves for each dataset with p < 0.0001 in (B). See Table S1A for 95% CI.
(C-H) MALDI-TOF mass spectrometry analysis of thermoactivity assays using DRMs associated wild-type g-secretase complex and purified wild-type or mutant APP C99 -3xFLAG substrates. (C) De novo AICD products at 37 C, (mean ± SEM, n R 4, except for I45F mean ± SD, n = 2) and (D-H) Ab products generated from the indicated APP substrate over the indicated temperature gradient. Ab product levels are normalized to total endopeptidase activity (total AICD levels); (mean ± SEM, n R 4, except for I45F mean ± SD, n = 2). Next, we studied in depth the processing of mutant APP substrates in a membrane-like environment (DRM). DRMs were prepared from insect cells expressing wild-type g-secretase (Acx et al., 2014) . g-Secretase products were directly quantified by MALDI-TOF and MALDI-FTICR mass spectrometry without any enrichment steps (Figures S6A-S6C ). Employing this approach allowed us to verify the production of Ab 45 (Figure S6C) , the stabilizing effect of the DRM and the relatively weak effect of pathogenic mutations in APP on AICD generation ( Figures S6D versus 4A) . We also confirmed the previously observed shift in the position of the ε-cleavage that favors the Ab 48 / Ab 42 product line linked to the T43I, V46F, and V46I substitutions, but not to the I45F variant (Bolduc et al., 2016; Chá -vez-Gutié rrez et al., 2012; Dimitrov et al., 2013 ) ( Figure 4C ). As shown above, E-S complexes containing Ab n peptides are more prone to destabilization. Thus, we analyzed how the pathogenic mutations in APP affect the temperature sensitivity of Ab generation. For the wild-type APP substrate, thermoactivity assays show progressive decrements in the generation of Ab 40 (major product) and increments in the Ab 43 precursor over the 37 C-65 C range ( Figure 4D ). Similarly, Ab 38 levels (minor product) gradually decline. Ab 38 is generated from both Ab 42 and Ab 43 (Matsumura et al., 2014; Okochi et al., 2013) ; thus, its decrement contributes partially to the increases in Ab 43 and the stabilized Ab 42 levels up to 58 C. Beyond 58 C, increased release of the precursor Ab 45 is seen in urea-based gel electrophoresis ( Figure 4J , 55 C). Similar analyses revealed that the T43I substitution increases the thermal susceptibilities for the Ab 38 , Ab 40 , Ab 42 , and Ab 43 products (compare Figure 4E to 4D), indicating a mutantinduced destabilizing effect on E-Ab n complexes. In support of this, T43I mutant Ab profiles show long Ab products at 37 C, and their levels increase with temperature ( Figures 4J and  S6E ). As the T43I mutation drastically shifts the position of the ε-cleavage to favor Ab 48 generation ( Figure 4C ), we speculate that the longer Ab products are Ab 45 and/or Ab 48 .
As previously reported, neither Ab 40 nor Ab 43 products are generated from the mutant I45F-APP substrate due to a mutant-induced product-line shift that involves the conversion of Ab 46 to Ab 42 (Bolduc et al., 2016) . Ab profiles confirmed the presence of Ab 38 and Ab 42 and showed the presence of a longer Ab product at 37 C, with Ab 46 mobility ( Figure 4J ). Increments in temperature induced progressive decrements in Ab 38 ( Figure 4F ) and increased Ab 42 and Ab 46 levels over the 37 C-65 C interval ( Figure 4J) .
Finally, the thermoactivity assays with V46F and V46I APP mutations show enhanced Ab 38 and Ab 42 decays (Figures 4G and 4H, respectively, and S6F) and increasing Ab 43 levels at temperatures above 50 C ( Figures 4G and 4H , respectively, and S6G), relative to the wild-type substrate. Thus, these pathogenic substitutions (in particular the V46F mutant) destabilize the g-secretase-Ab 43 interaction and may also impair mutant E-S complexes containing Ab peptides longer than 43 amino acids. We expressed transiently the V46F/I substrates in cells and quantified by ELISA secreted Ab 40 and Ab 43 peptides. The Ab 40 /Ab 43 ratio was reduced, confirming the destabilized g-secretaseAb 43 interaction ( Figure 4I ). V46F/I-Ab product profiles generated in DRM-based reactions support enhanced Ab 45 production from the V46I substrate at 55 C, relative to the wild-type DRM reaction ( Figure 4J ).
Overall, our data indicate that the T43I, I45F, and V46I mutations destabilize the E-S complexes with Ab 48 , Ab 46 , and Ab 45 , respectively, leading to dissociation and release of these long Ab peptides. Intriguingly, the V46F mutant destabilizes the ''wild-type'' g-secretase-Ab 43 complex. The V46F substitution drastically shifts the ε-cleavage position to favor the Ab 42 product line ( Figure 4C ) and nevertheless still generates substantial amounts of Ab 40 at 37 C ( Figure 4J ). This suggests that the phenylalanine substitution promotes the alternative cleavage of Ab 48 to Ab 43 (Ab 40 precursor) (Matsumura et al., 2014) . However, the additional effects of this mutation on docking/presentation of the substrate to the catalytic site and/or endopeptidase cleavage specificity (different AICD, and therefore long Ab products are generated; Figure 4C ) may contribute to the observed effects. Together, our data demonstrate that APP mutations located around the g-cleavage sites impact the stability of E-Ab n complexes and consequently enhance product dissociation and the release of long amyloidogenic Ab by a similar mechanism to that proposed for PSEN mutations ( Figure 4B ).
Exogenous Factors Stabilize or Destabilize g-Secretase-Substrate Interactions
Previous studies have shown that diverse compounds, referred to as g-secretase inverse modulators, mimic FAD-linked mutations by enhancing Ab 42 generation from the wild-type enzyme (Kukar et al., 2005) . In contrast, g-secretase modulators (GSMs) (Weggen et al., 2001) , including endogenous metabolites (Jung et al., 2015) , enhance protease processivity (Chá -vez-Gutié rrez et al., 2012; Takeo et al., 2014) . However, their mechanisms of action have remained elusive.
We tested three different GSM chemistries ( Figure 5A ) in g-secretase thermoactivity assays. As expected, the direct g-secretase modulators GSM A and B and the inverse modulator fenofibrate (GSM C) (Kukar et al., 2005) increased and decreased the conversion of Ab 42 to Ab 38 at 37 C, respectively ( Figure 5B ). Most notably, the addition of 10 mM direct GSM to wild-type enzyme maintained elevated protease processivity (Ab 38 /Ab 42 ) over the 37 C-55 C interval ( Figure 5B ), thus apparently stabilizing the g-secretase-Ab 42 interaction. The compound-mediated stabilization is also observed to a certain extent at the endopeptidase level (AICD production), especially with GSM B ( Figure 5C ).
Remarkably, fenofibrate leads to important reductions in AICD production at increasing temperatures, which is indicative of a strong destabilizing effect on g-secretase-APP substrate complexes. Our data provide mechanistic insights into the mode of action of therapeutically relevant compounds. Furthermore, these results highlight the possibility that environmental factors affecting the stability of the most labile E-S complexes (containing short Ab n ) could alter the risk for sporadic AD.
Elevation in Body Temperature
Modulates g-Secretase Activity In Vivo Given the observed high thermal susceptibility of the PSEN/gsecretase activity ( Figure 1I) , we evaluated the effect of elevated temperature in intact cells. To this end, we incubated HEK293 cells stably overexpressing human APP695 KM670/671NL (Swedish mutation) for 1 hr at 37 C or 42 C. Cell viability was not affected by this short incubation time. ELISA quantification of secreted Ab showed a significant increase of total Ab produced, especially Ab 43 ( Figures 6A and 6B ) and a significant reduction in the (Ab 38 +Ab 40 )/(Ab 42 +Ab 43 ) ratio (products/substrates of the 4 th catalytic cycles) at 42 C, relative to 37 C ( Figure 6C ). Next, we wondered whether increased body temperature could modulate g-secretase activity in vivo. We induced fever in mice carrying humanized Ab sequence and the AD-linked Swedish (KM670/671NL) APP mutation (Saito et al., 2014) . Treated mice received an injection of 30 mg LPS intraperitoneally and were kept in a warmed cage ($38.5 C) (Jiang et al., 1999) . The treated mice reached a body temperature of 40 C (±0.5 C) 25 min post-injection, which was maintained for maximally 2 hr ( Figure S7 ). Control animals injected with saline solution and kept at room temperature (RT, $23 C) had body temperatures around 38 C. Quantification of steady-state Ab levels in plasma by ELISA revealed increased total Ab levels (1.88-fold) in treated versus control mice and relative increments of 1.51-, 1.94-, and 1.82-fold for Ab 38 , Ab 40 , and Ab 42 , respectively ( Figure 6D) . Accordingly, the Ab 38 /Ab 42 ratio is lowered in the treated mice ( Figure 6E ). Other factors than elevated body temperature might have contributed to the observed changes in Ab; however, the results obtained in cell culture provide support to the in vivo findings. The fact that elevated body temperature augments g-secretase activity and impairs the efficiency of the 4 th g-cleavage further supports the idea that exogenous factors may impact g-secretase-Ab n metastable structures.
DISCUSSION
In this study, we have shown that clinical mutations in PSEN and in APP destabilize primarily the intermediary E-S complexes involved in the sequential processing of APP by g-secretase, leading to enhanced E-S dissociation and thereby release of longer and more amyloidogenic Ab peptides. We used progressive thermal destabilization of the wild-type enzyme to evaluate the strength of the different E-S interactions ( Figures  1A and 1E ) and demonstrated that increments in temperature mimic the effects of clinical AD mutations. Our studies reveal a direct correlation between substrate length and E-S complex stability, indicating that each g-secretase cleavage reduces the stability of the subsequent E-S complex and thereby progressively shifts the equilibrium toward dissociation and Ab release. Direct determination of the Michaelis constants for APPC99 (Km $400-800 nM [Chá vez-Gutié rrez et al., 2012; Funamoto et al., 2013] ) and for Ab 46 , Ab 45 , or Ab 43 substrates (Km $3 mM, Table  S2 ) as well as relative affinities for APPC99, Ab 43 , Ab 40 , and Ab 38 ( Figure S3A ) support this concept.
We propose that g-secretase-APP C99 complexes are stabilized by a network of weak bonding interactions along the substrate transmembrane domain (TMD) (global fitting). In this scenario, the stabilizing binding energy depends critically on the area of interacting surface, i.e., on the substrate length, while the side chains of the constituting residues are not the main driving force for the formation nor for the stabilities of the E-S complexes. This view is supported by the known relaxed g-secretase substrate specificity. However, in sharp contrast, we observed that single amino acid substitutions in APP can exert a profound destabilizing effect on E-Ab n, complexes, which translates into altered Ab profiles. These findings imply that the type of interactions involved in the stabilization of the initial ε-E-S versus the consecutive g-E-S complexes are fundamentally different.
While the nature of the E-S interaction remains unknown, the recent structure of g-secretase in complex with a co-purifying type I transmembrane protein provides interesting insights. As shown in Figure 7 , a short helical structure anchors the putative substrate to PSEN-NTF, while an unstructured stretch of approximately five amino acids extends through a wide channel to reach the catalytic residues (Bai et al., 2015b) . In our view, this co-structure could illustrate how a de novo Ab n product interacts with PSEN before it engages in the next catalytic cycle or is released. In the former case, further unwinding of the N-terminal helix must occur in order to fill the S1 0 -S3 0 enzyme pockets (Bolduc et al., 2016) during catalysis (Figure 7 ). This will lead to further destabilization of the anchor helix, which weakens the E-S assembly, and importantly, will confer progressively more significance to other (side-chain dependent) interactions along the de novo Ab n substrate. This model provides an explanation for why AD-linked substitutions in APP (Ab 42-46 ) destabilize g-secretase-Ab but not g-secretase-APP C99 complexes. The presented data indicate that Ab 45 and Ab 46 substrates are of a critical length as the following g-cut drastically reduces the stability of the subsequent g-secretase-Ab 43/42 complexes ( Figures 3C and 3F) . According to the E-Ab interaction model (Figure 7) , this can best be understood by taking into account the fact that unstructured C-terminal stretches of $5 amino acids (aa) leave N-terminal helical anchors of 13 aa, 12 aa, 10 aa, or 9 aa in the Ab 46 , Ab 45 , Ab 43 , or Ab 42 peptides, respectively. It appears that an N-terminal helical anchor with at least three turns (Ab 46 ) stabilizes E-S interactions and promotes efficient g-processing.
Pathogenic PSEN1 mutants, irrespective of their nature or position, destabilize E-S complexes (Figure 3) , and previous work analyzing the ε-cleavage shows that their effects are not explained by lower substrate affinities but rather by reduced catalytic rates (decreased Vmax; see also Table S2 ). Similarly, elevated temperature lowers Ab processing efficiencies by reducing proteolytic rates. This indicates that thermal-or mutant-induced destabilization does not affect directly the formation of g-secretase-Ab n complexes but instead disturbs a subsequent step in catalysis. In agreement, FAD-linked mutants in PSEN do not directly affect APP C99 -nor Ab n -substrate binding to g-secretase ( Figures S3C and S3D) . Furthermore, the stabilizing GSM B compound does not change APP C99 nor Ab 43 binding to the wild-type complex ( Figure S3B ). Thus, destabilization of the productive E-S interactions is not due to alterations in the initial formation of g-secretase-APP complexes but a consequence of thermal/mutant/compound-induced disturbances during the subsequent catalysis.
Upon E-S formation, the complex can either decompose back to free enzyme and substrate or undergo catalysis via a transition state intermediate (E-S* complex), which involves structural rearrangements in both the enzyme and the substrate. The g-secretase proteolytic mechanism likely involves, as explained, local helix unwinding prior to cleavage, and the resultant Figure S4 ). Tukey boxand-whiskers plots for (D) ELISA0quantified Ab steady-state levels in plasma and (E) the Ab 38 / 42 ratio show increased secreted P Ab (Ab 38 +Ab 40 +Ab 42 ) levels and a significant reduction in protease efficiency (4 th catalytic turnover) in the fever group after 100 min fever period, respectively. Ten control and ten treated animals were tested, unpaired two tailed t tests, *, **, ***, and **** indicate P values % 0.05, 0.01, 0.001, and 0.0001, respectively.
backbone break must have a destabilizing effect on the remaining helical structure of the subsequent de novo Ab n substrates (Figure 7 ).
Although our knowledge of intramembrane proteolytic mechanisms remains very limited, insights from the rhomboids are already very apparent. For instance, the substrate (TMD) helical propensity is likely pivotal to the E-S interaction, and proteolysis is driven by reaction kinetics rather than substrate affinity (Dickey et al., 2013; Moin and Urban, 2012) . We propose that FAD-linked PSEN mutations, or increased temperature, disturb the stabilization of the E-S* transition state, promoting non-productive dissociation (E-S*/ E+S) or restoration of the E-S state (E-S ) E-S*). In support, FAD-linked G384A and Delta Exon 9 PSEN mutations decrease the affinity for the transition-state analog L-685,458 (Svedru zi c et al., 2012). In the case of the APP-CTF substrate, which remains anchored to the membrane, a destabilizing effect implies the re-initiation of the proteolytic process (E-S formation). The situation is fundamentally different in the case of Ab n substrates, as they are no longer anchored in the membrane and their release and dilution into the extracellular milieu makes re-association with the enzyme unlikely. In support of our model, others have shown that PSEN pathogenic substitutions increase the dissociation rate of the g-secretase-Ab 42 complex (Okochi et al., 2013) .
It is highly relevant that both APP and PSEN mutants promote the release of relatively long Ab R43 peptides. Thus, while increments in toxic Ab 42 are proposed as drivers of FAD (Potter et al., 2013) , our findings raise the possibility that even longer Ab species may have high pathogenic relevance.
Our studies help to understand the mechanism of action of a major class of drug candidate for AD therapeutics targeting g-secretase, i.e., the GSMs ( Figure 5 ). The same holds true with regard to the inverse correlation between generation of long Ab 42/43 peptides and membrane thickness (Holmes et al., 2012; Winkler et al., 2012) and the high sensitivity of g-secretase function to lipid environment changes (Holmes et al., 2012; Osenkowski et al., 2008) .
Besides providing fundamental novel insights into the working of g-secretase, the current report raises some additional interesting pathophysiological considerations. The significant changes in g-secretase processivity observed upon mild temperature increments in vitro and in vivo suggest that fever could promote amyloidogenic Ab generation. While further work is needed to investigate the relationship between fever and the occurrence of AD, it is interesting to notice that carriers of the M694V pyrin mutation associated with familial Mediterranean fever have been found to have a 3-fold higher risk for sporadic early-onset AD than those who were homozygous for the normal allele in an Italian population (Arra et al., 2007) . Whether this is caused by the occurrence of fever or other (unknown) effects of the mutation remains to be investigated.
In conclusion, our findings reveal substantial insights into the structural and kinetic g-secretase mechanisms and support a unifying model for AD-causative mutations that places generation of longer Ab peptides central to AD pathogenesis. Furthermore, these studies provide a novel conceptual framework for investigating g-secretase (dys)function in sporadic AD, as the demonstrated fragility of g-secretase processivity suggests that mechanisms similar to those underlying FAD may increase the risk of sporadic AD in a subgroup of patients (Szaruga [Bai et al., 2015b] ) with the structure of APP C99 (purple) (PDB: 2LP1, [Barrett et al., 2012] ) manually docked in the putative substrate binding (see Figure S1A3 . (A) C99 or (C) Ab n interacts with PSEN before it engages in the next catalytic cycle (E-S*) or is released (E+S) (B-D) . N-terminal transmembrane helix unwinding (B and D) occurs in order to fill the S1 0 -S3 0 enzyme pockets (Bolduc et al., 2016) during catalysis. The progressive shortening of the N-terminal anchor progressively destabilizes g-secretase-Ab n complexes, shifting the equilibrium toward dissociation (Ab n release). et al., 2015) . Finally, our findings may guide novel efforts to develop safe therapies that target g-secretase, i.e., the generation of g-secretase (E-S) stabilizing compounds (GSSC) for the prevention and treatment of AD.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture Sf9 and Hi5 cells were cultured in Insect-XPRESS protein-free medium (Lonza) at 27 C. HEK293 APP 695 KM670/671NL (Swedish) and COS-1 cells lines were cultured in Dulbecco's modified Eagle's medium/F-12 (Invitrogen), 10% fetal bovine serum (GIBCO).
In vivo animal studies Female APP NL mice, eleven to sixteen week old (Saito et al., 2014) .
METHOD DETAILS
Antibodies and reagents Antibodies were purchased as follows: anti-FLAG M2 from Sigma, Alexa 790 Goat anti-Mouse IgG from Invitrogen, 82E1 against human Ab (N-term) from IBL, biotinylated anti-mouse IgG from Vector Laboratories and streptavidin-HRP from GE Healthcare. ELISA antibodies and g-secretase modulators were obtained through collaboration with Janssen Pharmaceutica NV, Beerse, Belgium: JRF AB038 for Ab1-38, JRF/cAb40/28 for Ab1-40, JRF/cAb42/26 for Ab1-42 and detection antibody JRF/AbN/25 against the N terminus of Ab. Elisa kit against amyloid b (1-43) (FL) was purchased from IBL, AlphaLISA Detection Kit against amyloid b (1-40) was purchased from PerkinElmer. Fenofibrate was purchased from Sigma Aldrich. Synthetic b-Amyloid 1-38, 1-40, 1-42, 1-43 and 1-46 were purchased from rPeptide and 1-45 from Anaspec. b-Amyloid 1-43 used as standards in ELISA was from IBL and 1-40 standard in AlphaLISA from PerkinElmer. g-Secretase inhibitor X purchased from Calbiochem. Complete protease inhibitor tablets were purchased from Sigma-Aldrich. All reagents for MALDI-Mass Spectrometry used in this study were of HLPC grade. Acetonitrile (ACN) and trifluoroacetic acid (TFA), were purchased from Merck (Darmstadt, GER). Milli-Q water (ddH 2 O; Millipore) was prepared Expression and purification of wild-type APP C99 , wild-type and mutant APP C99 -3xFLAG and wild-type Notch-based 3xFLAG substrates Human wild-type and mutant (T43I (T714I), I45F (I716F), V46F (V717F) and V46I (V717I)) APP C99 -3xFLAG and Notch-based (Notch3xFLAG) substrates were expressed in COS1 or HEK293 cells. Briefly, cells were transiently transfected with pSG5-APP C99 -3xFLAG (wild-type or mutant) or pSG5-Notch-3xFLAG vector. Before collection, cells expressing C99-3xFLAG were treated overnight with 10 mM GM GM6001 inhibitor (Sigma) to prevent its conversion to C83-3xFLAG. Cells were harvested and resuspended in 50mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1X PI and incubated on ice for 1 hr. Membrane-solubilized protein fractions were obtained by ultracentrifugation at $200000 g for 20 min. Wild-type APP C99 substrate with a PreScission Protease cleavage site and 3X-FLAG-tag (APP C99 -PPS-3X-FLAG) at the C terminus was cloned in the pAcAB4 vector and expressed in Hi5 insect cells. Cells were collected 48-72 hr post infection and resuspended in 50mM Tris-HCl pH 7.6, 150 mM NaCl, 1X PI. Total membranes were prepared and rinsed twice in 1x TBS, 1M NaCl and complete protease inhibitor mixture. Membranes were solubilized ON in 1x TBS, 1% n-dodecyl b-d-maltopyranoside (DDM; Anatrace) and 1X PI at 4 C. Membrane-solubilized protein fractions were obtained by ultracentrifugation at $200000 g for 45 min.
FLAG-tagged recombinant substrates were purified by immunoaffinity chromatography using the anti-FLAG M2-agarose beads (Sigma), according to the manufacturer's protocols. All substrates, except for the APP C99 -PPS-3X-FLAG, were eluted in 100mM glycine HCl, pH 2.7, 0.25% n-dodecyl b-D-maltoside (Sigma) and immediately neutralized to pH 7 by the addition of Tris-HCl, pH 8.0. Digestion with GST-tagged PreScission protease eluted APP C99 -PPS-3X-FLAG in 25mM Pipes, 150mM NaCl, 0,02% DDM, 0,5mM EDTA and 1mM DTT. Removal of the PreScission protease was done by immunoaffinity pulldown using Glutathione Sepharose 4B (GE Healthcare). Purity was assessed by SDS-PAGE and Coomassie staining (InstantBlue Protein Stain, Expedeon).
Expression and purification of g-secretase complexes
Human wild-type or mutant (P88L, Y115H, M139V, L166P, R278I, E280A, G384A, L435F) PSEN1, NCT-GFP, APH1AL and PEN2 cDNAs were cloned into the pAcAB4 transfer vector (BD Biosciences). Co-transfection of the transfer vector (containing the heterologous genes) and flashBacGold TM DNA (Oxford Expression Technologies) in Sf9 cells allowed homologous recombination and production of baculoviruses bearing the four essential subunits of the g-secretase complex. A PreScission Protease cleaving site (LeuGluValLeuPheGln/GlyPro) and GFP were cloned at the C-terminal site of NCT. Protease complexes were expressed in Hi5 insect cells. Infected Hi5 cells were collected at 72 hr post infection and lysed in 2% CHAPSO (Anatrace) buffer (25 mM Pipes pH 7.4, 300 mM NaCl, 5% Glycerol, 1X Protease inhibitors (PI). Affinity purification was carried out using a high affinity anti-GFP nanobody covalently coupled to agarose beads (NHS-activated beads, GE Healthcare) in a 3:1 ratio (mg:ml). PreScission protease cleavage between NCT and GFP eluted untagged g-secretase complexes (buffer composition: 25 mM Pipes pH 7.4, 150 mM NaCl, 0.5% CHAPSO, 5% Glycerol). Finally, removal of the GST-tagged PreScission protease by immunoaffinity pulldown using Glutathione Sepharose 4B (GE Healthcare) was performed and the purity of g-secretase complexes was assessed by SDS-PAGE and Coomassie staining (InstantBlue Protein Stain, Expedeon).
Subjects
Human cortical specimens were obtained throughout collaboration with Queen Square Brain Bank for Neurological Disorders at University College London. All of the samples came from brains that were removed and placed in À80 C within 42 hr postmortem. Samples were collected following protocols approved by respective ethical boards and written legal consents for the use of organs for medical research are available for each patient. All human protocols were approved by Medical Ethics Committee UZ KU Leuven, Belgium.
Detergent resistant membrane preparation from insect cells and human brain samples CHAPSO detergent resistant membranes (DRMs) were prepared from Hi5 insect cells overexpressing PSEN1/APH1A g-secretase complexes (WT or mutant complexes containing PSEN1 pathogenic mutations P88L, Y115H, M139V, L166P, R278I, E280A, G384A or L435F) or human brain frontal cortices (after careful removal of leptomeninges and blood vessels). In case of human brain samples, around 200 mg blocks of tissue were homogenized in $10 volumes of 10% sucrose in MBS buffer (25mM MES, pH 6.5, 150mM NaCl) containing 1% CHAPSO (Sigma) and 1X PI. DRMs from insect cells were prepared from total membranes (200 mL Hi5 cell culture). Membrane pellets were homogenized in $2.5 mL of 10% sucrose in MBS buffer containing 1% CHAPSO (Sigma) and protease inhibitors. Brain or cell membrane homogenates were mixed with equal volume of 70% sucrose in MBS buffer, 4 mL was placed at the bottom of an ultracentrifuge tube (Beckman, 344059) and successively overlaid with 4 mL of 35% sucrose (MBS) and 4 mL of 5% sucrose (MBS). Samples were centrifuged at 39,000 rpm for 20 hr at 4 C on a SW 41 Ti rotor (Beckman). After centrifugation the DRM fraction (interface of 5%/35% sucrose) was carefully collected, rinsed in 20mM PIPES, pH 7, 250mM sucrose, 1M EGTA and recentrifuged twice (100,000 g, 60 min, 4 C). The resultant pellet was resuspended with above buffer and stored at À80 C until use.
Evaluation of g-secretase activity in cell culture
To assess the effect of elevated temperature on Ab production, HEK293 cells stably expressing human APP 695 KM670/671NL (Swedish) were plated at 1X10 6 cells/9 cm 2 well; after 24h, cells were washed with serum-free media and medium refreshed (1ml). Cells were immediately placed at 37 or 42 C and after 1h incubation the extracellular media was collected for Ab ELISA analyses and cell viability was assessed (trypan blue staining). To determine the effects of mutations in APP on Ab production, wild-type HEK293 cells were transfected with pSG5-based expression vectors bearing wild-type or mutant APPC99-3xFLAG cDNAs. At 36h post-transfection, cells were rinsed and medium refreshed. Extracellular media was collected after 4h incubation at 37 C. For all experiments, cells were cultured in Dulbecco's modified Eagle's medium/F-12 containing 10% fetal bovine serum and sAb were analyzed by MSD ELISA.
g-Secretase in vitro thermoactivity assays Proteolytic reactions were performed using purified $10nM PSEN1/APH1A g-secretase complexes and purified recombinant FLAG tagged substrates in 0.25% CHAPSO, 2.5% DMSO (or 10mM GSM, 100mM Fenofibrate), 0.1% Phosphatidylcholine, 150mM NaCl and 25mM PIPES over a temperature gradient ranging from 37 C-65 C for 20 min (except for the severe P88L mutant protease which activity was measured after 1h incubation and with 10X more enzyme). Enzyme mixes (containing all components except the substrate) and substrate dilutions were pre-incubated separately at the indicated temperatures for 10 min. After pre-incubation, substrate was added to the enzyme mix and proteolysis proceeded for 20 min or 1h (P88L). Final substrate concentrations in assays were 1.75 mM C99-3xFLAG or 2mM Notch-3xFLAG unless otherwise indicated.
g-Secretase thermoactivity assays using Ab 43 , Ab 45 or Ab 46 synthetic peptides as substrates and purified wild-type g-secretase were carried out as indicated above with the following modifications: synthetic Ab peptides were diluted in DMSO and proteolytic reactions were incubated for 1 hr (Ab 45 or Ab 46 ) or 4h (Ab 43 ) at the indicated temperatures.
Thermoactivity analyses using DRMs as source of enzyme were performed similarly, but reactions contained 0.6 mg/ml or 1 mg/ml protein for DRMs prepared from Hi5 insect cells overexpressing g-secretase components or human brain samples, respectively. Assays were carried out for 20 min for DRMs derived from insect cells or 4h for DRMs prepared from human brain samples in saline MBS buffer (150mM NaCl, 25mM MES), 0.1% DMSO, 1mM EGTA and protease inhibitors (Complete, ROCHE) with purified substrates at saturating concentrations. Temperature gradients ranging from 37 C-60 C and 60 -80 C were set for DRM analyses. All thermoactivity assays were performed on a PCR thermocycler (Biorad T100).
Quantification of g-Secretase endopeptidase activity g-Secretase endopeptidase products (ICD-3XFLAG) generated in the proteolytic assays were quantified by SDS-PAGE western immunoblot and/or MALDI-MS (see MALDI-MS analysis). In the first case, reactions were mixed with one volume of methanol-chloroform (1:2, v/v) to remove hydrophobic molecules (lipids, substrate and membrane proteins) and aqueous fractions containing ICD products were analyzed by SDS-PAGE western immunoblot using anti-FLAG M2 antibody and quantified with Odyssey infrared imaging system. Quantification of Ab production by ELISA Ab 38 , Ab 40 (except for quantification of Ab 40 from proteolytic reaction using Ab 43 as substrate, which was quantified using AlphaLISA Detection Kit from PerkinElmer according to manufacturer's protocol) and Ab 42 product levels were quantified on Multi-Spot 96 well plates pre-coated with anti-Ab 38 , Ab 40 , and Ab 42 antibodies obtained from Janssen Pharmaceutica using multiplex MSD technology. MSD plates were blocked with 150 ml/well 0.1% casein buffer for 1.5 hr at room temperature (600 rpm) and rinsed 5 x with 200 ml/well washing buffer (PBS + 0.05% Tween-20). 25 mL of SULFO-TAG JRF/AbN/25 detection antibody diluted in blocking buffer was mixed with 25 mL of standards (synthetic human Ab 38 , Ab 40 , Ab 42 peptides) or reaction samples diluted in blocking buffer and loaded 50 mL per well. For the quantification of Ab peptides generated in activity assays using synthetic Ab 43 , Ab 45 and Ab 46 as substrates, reactions with no enzyme were loaded to determine background levels. After overnight incubation at 4 C plates were rinsed with washing buffer and 150 ml/well of the 2x MSD Read Buffer T (tris-based buffer containing tripropylamine, purchased from Meso Scale Discovery) was added. Plates were read immediately on MSD Sector Imager 6000. Ab43 product levels were quantified with b-Amyloid 1-43 kit from IBL according to manufacturer's instructions. Ab 38 , Ab 40 and Ab 42 product levels in proteolytic reactions using DRMs were analyzed by MALDI-MS (see below).
Detection of Ab product profiles in Urea gels
Ab-products were analyzed in urea-based bicine/tris SDS-PAGE (Wiltfang et al., 2002) . Gel thickness was kept at 0.75mm and the composition of the separation gel was as follows: 8M Urea, 11% T/5% C polyacrylamide, 0.4M H 2 SO 4 , 0.25% SDS, pH = 8.1. Electrophoresis was conducted at constant 100V for around 2h, after that, gels were transferred to a PVDF membrane and western immunoblot with 82E1 antibody, biotinylated anti-mouse IgG and streptavidin-HRP was performed. Signals were detected using ECL chemiluminescence with Fujifilm LAS-3000 Imager. measurements was done as previosly described. Data were acquired in positive ion mode from 150 to 10,000 m/z using magnitude mode and 4M data size with a resolving power of 390,000 at m/z 400 and $40,000 at m/z 4,000, respectively, and a free induction decayof 2.9 s. The following tuning parameters were used; Ion transfer (Funnel 1 100 V 2+ m/z 4280.815633). Spectra recalibration was done by performing a one-point intenal recalibration on the most promiment amyloid beta signal in the analysis and was done using the software Data Analysis 4.4 (Bruker Daltonics). Computational analysis and mass matching were performed using the Bruker Biotools 3.2 SR5 (Bruker Daltonics) software.
Elevation of body temperature in mice
Eleven to sixteen-week-old female APP NL mice were injected intraperitoneally with 30 mg of LPS (Sigma-Aldrich) in 500 ml of sterile saline. Age-matched control were treated simultaneously with saline only. Mice injected with LPS were immediately placed in cages preheated with a heating pad, a red light lamp and a 60 W bulb to $38.5
C. Mice core body temperature raised within 25 min to 40 C (±0.5 C) and then maintained at 39.9 C (±0.6 C) for 100 min ( Figure S5 ). Mice rectal temperature was monitored every 25 min (see Figure S4 ). Control mice were kept at room temperature (RT, (22) (23) (24) and subjected to the same handling. At the end of the experiment mice were sacrificed in CO2 and decapitated. Collected blood was used to isolate plasma by 10 min centrifugation at 1500 g. Ab 38 , Ab 40 , and Ab 42 steady-state levels in plasma were analyzed by ELISA (multiplex MSD technology). The protocol was approved by ethical committee of KU Leuven (project number: 142/2015).
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analysis was performed using GraphPad Prism 7 software. Statistical details of particular experiments are described in the manuscript text and/or figure legends. GraphPad Prism software was used to fit the thermoactivity data in Figure 1B , 1E, 1G, 3C, 3D, 4A, 4B, S3A-S3D, and Figure S4C to Gaussian curves in order to estimate Tm production temperatures by interpolation. Michaelis-Menten curve of g-secretase activity was used to calculate Km and Vmax in Figures 2B and 2E and S2. Statistical evaluation of MALDI-MS data of drug/temperature effects on g-secretase Ab/AICD activity, were done on total ion count normalized (CPT) average mass spectra. Briefly, eight single mass spectra were processed as described above, and average intensity values (arbitrary units) were extracted for defined Ab peptides or AICDs within a mass tolerance window of 500 ppm and transferred to GraphPad Prism software for further analysis and visualization. Linear MALDI TOF MS signals corresponding to amyloid beta were confirmed by high resolution MALDI-FT-ICR analysis with a mass accuracy <<5ppm. Figure S1 . g-Secretase Structure with APP C99 Manually Docked and Ab Profiles Generated in Membrane-like Conditions, Related to Figure 1 (A)(1) 3D structure of the wild-type human g-secretase (PSEN1/APH1a) in complex with the putative substrate (PDB: 5fn2, (Bai et al., 2015b) ). NCT in green, APH1 in yellow, PEN2 in brown, PSEN in beige and the putative substrate peptide in red. Lateral and (2) bottom views of the membrane core and (3) manual docking of the APP C99 substrate (purple) (2LP1, (Barrett et al., 2012) ) into the putative substrate binding pocket of the g-secretase complex. (B and C) DRMs prepared from human control brain samples tested in in vitro activity assays using 1.5mM purified wild-type APP C99 -3xFLAG substrate. (B) ELISA quantifications (mean ± SD, n = 2) and analysis of Ab product profiles in urea-based gels show enhanced g-secretase processivity (relative to detergent solubilized conditions (Figure 1C, 37 C) ). Ab 40 is the main product, similar to profiles generated in cell-based assays. The results support a stabilizing effect of the membrane environment. aggregates. The remaining soluble fraction was subjected to semiquantitative SDS-PAGE/western blot and assessed for the levels of PSEN1 NTF and PSEN1 CTF. (A) Quantification of the relative soluble amounts of WT versus AD-linked PSEN1 N-terminal and C-terminal fragments at the distinct temperatures were used to infer the intrinsic PSEN thermal stabilities (n R 6, average ± SE) and (B) reveal significant destabilization of the tested pathogenic PSEN1 mutants at 55 C when compared to WT protease (Statistical significance: Anova and Dunnett's post-test, *p % 0.1, **p % 0.01, ***p % 0.001).
Supplemental Figures
(C) Biotinylated g-secretase -His-tagged Nb interaction was measured using a bead-proximity assay (AlphaScreen). 10 nM biotinylated g-secretase complexes were pre-incubated with 10 nM purified His-tagged nanobody Nb4 or Nb28 in the presence of donor and acceptor beads for 45 min at 30 C. The mix was then subjected to different temperatures over a gradient from 37 to 70 C for 1h. g-Secretase-Nb mixes were brought back to 25 C prior to Alpha-Screen binding detection.
Right panel (Nb4) and left panel (Nb 28) show the progressive destabilization of Nb-g-secretase complexes for wild-type and 3 selected FAD mutants (PSEN L166P, E280A and G384A) over temperature. A significant shift in the temperature at which the g-secretase-Nb interaction drops to 50% of its initial levels is observed ( Figure S4C , dotted line), indicating that mutant protease complexes have relatively lower thermostabilities than the wild-type (for both Nb-analyses n R 5, average ± SE, Temperature versus normalized signal data was fit to Y = 100/(1+(X^HillSlope)/(IC 50 HillSlope)), different curves for each dataset with p < 0.0001. Urea-based gel electrophoresis confirms production of only long Ab peptides (RAb 43 ) from these protease complexes at 37 C (Liu et al., 2017; Ohki et al., 2014; Saito et al., 2011; Veugelen et al., 2016) . (legend continued on next page)
